Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTSQC14)

DTT Name	Palmitoyl-protein thioesterase 1 (PPT1)
Synonyms	Palmitoyl-protein hydrolase 1; PPT-1; PPT; CLN1
Gene Name	PPT1
DTT Type	Clinical trial target	[1]
BioChemical Class	Palmitoyl thioesterase
UniProt ID	PPT1_HUMAN
TTD ID	T97740
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
EC Number	EC 3.1.2.22
Sequence	MASPGCLWLLAVALLPWTCASRALQHLDPPAPLPLVIWHGMGDSCCNPLSMGAIKKMVEK KIPGIYVLSLEIGKTLMEDVENSFFLNVNSQVTTVCQALAKDPKLQQGYNAMGFSQGGQF LRAVAQRCPSPPMINLISVGGQHQGVFGLPRCPGESSHICDFIRKTLNAGAYSKVVQERL VQAEYWHDPIKEDVYRNHSIFLADINQERGINESYKKNLMALKKFVMVKFLNDSIVDPVD SEWFGFYRSGQAKETIPLQETSLYTQDRLGLKEMDNAGQLVFLATEGDHLQLSEEWFYAH IIPFLG
Function	Prefers acyl chain lengths of 14 to 18 carbons. Removes thioester-linked fatty acyl groups such as palmitate from modified cysteine residues in proteins or peptides during lysosomal degradation.
KEGG Pathway	Fatty acid elongation (hsa00062 ) Metabolic pathways (hsa01100 ) Fatty acid metabolism (hsa01212 ) Lysosome (hsa04142 )
Reactome Pathway	Fatty acyl-CoA biosynthesis (R-HSA-75105 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Plitidepsin	DMJ8AUE	Multiple myeloma	2A83	Phase 3	[1]
TSHA-118	DMLMV7V	CLN1 disease	5C56.1	Phase 1/2	[2]
------------------------------------------------------------------------------------

References

1	Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B
2	Clinical pipeline report, company report or official report of Taysha Gene Therapies